Kamada Ltd.

Foreign Filer Report • May 20, 2015

_________ false

C002����� ��"�2PublicKAMADA LTD9024Corporation no: 511524605Stock Exchange/Market: -11934380Sapir 7 P.O.B 4081 , Ness-Ziona 74036 , ISRAEL ,Tel: 08-9406472 , Fax: 08-9406473E.mail address: liatc@kamada.comReported via MAGNA: 20/05/2015              Time of broadcast: 08:38 08:35:30

Company site:		www.kamada.com

Reference: 2015-02-023406

Israel Securities Authority		Tel Aviv Stock Exchange
www.isa.gov.il		www.tase.co.il

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

The corporation is a foreign private issuer as defined by U.S. Securities Laws.
Attached hereto is a report on Kamada reported updated data from the Company�s European and Canadian Phase 2/3 clinical study of inhaled Alpha-1 antitrypsin (AAT) to treat alpha-1 antitrypsin deficiency (AATD) during a panel discussion entitled: �New Treatment Prospects for AATD Patients: Results from a Phase 2/3 Inhaled AAT Trial.� The panel, led by Key Opinion Leaders (KOLs) who specialize in treating patients with AATD, was held during the American Thoracic Society (ATS) 2015 International Conference held from May 15-20, 2015 in Denver, Colorado. The slides from the presentation are attached as Exhibit 99.1 and are also available on the Company�s website at www.kamada.com
ATS_2015_ppt__19515_final_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Previous names of reporting entity:
Date of revision of form structure: 15/04/2015
- - -
Name of the Signatory: : Cohen Liat , Position of Signatory in the reporting corporation: Company Controller , Name of Employer Company: .
Sapir Telephone: 08-9913168 , Facsimile: 08-9912183 , E-mail: liatc@kamada.com 1